Navigation Links
ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
Date:10/31/2012

CAMBRIDGE, Mass., Oct. 31, 2012 /PRNewswire/ -- ViThera Pharmaceuticals, Inc, a developer of novel therapeutics based on engineered probiotic bacteria, announced today the publication of breakthrough data validating its approach for the delivery of elafin in treating gastrointestinal inflammation. The results were published today by the journal Science Translational Medicine and show use of recombinant probiotic and non-pathogenic food-strain bacteria to deliver elafin, a protein designed to protect human mucosal tissue during inflammation. The publication by senior author Nathalie Vergnolle and ViThera co-founder Philippe Langella describes a series of preclinical experiments successfully validating elafin as a novel treatment approach with future applications for human inflammatory bowel disease (IBD).

ViThera's President, Johannes Fruehauf, commented, "We are excited about the recognition that this publication entails and we congratulate Nathalie and Philippe on this important achievement." ViThera has obtained worldwide exclusive rights to the technology and is developing it further towards validation in clinical trials in close collaboration with Dr. Vergnolle and Dr. Langella. ViThera's VT301 program, currently in preclinical development, focuses on restoring and maintaining the integrity of the gut epithelium in patients with IBD by delivering elafin. This treatment is designed to help patients with active disease achieve remission faster and patients in remission to avoid flare-ups. VT301 is expected to enter clinical trials in two years for patients with mild to moderate ulcerative colitis.

About ViThera Pharmaceuticals

ViThera is a startup biotechnology company based in Cambridge, Massachusetts. Its research combines innovative molecular biology with the benefits of probiotics to create therapeutics for a variety of chronic diseases, including inflammatory bowel diseases like Crohn's disease and ulcerative colitis. ViThera is using its EnLact™ platform, combining synthetic biology in engineered probiotic bacteria to deliver therapeutic molecules in the gastrointestinal (GI) tract. ViThera is privately owned. www.vitherapharma.com


'/>"/>
SOURCE ViThera Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
2. S*BIOs Novel JAK2 Inhibitor Pacritinib (SB1518) and Histone Deacetylase Inhibitor Pracinostat (SB939) Demonstrate Promising Activity in Phase 2 Studies for Patients with Myelofibrosis (MF)
3. New magnetic-field-sensitive alloy could find use in novel micromechanical devices
4. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
5. TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
6. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
7. Nabsys Expands Leadership Team to Prepare for Commercialization of Novel DNA Positional Sequencing Technology
8. Boulder Diagnostics Licenses Novel Rapid Detection Technology for Homocysteine and Related Compounds from Portland State University
9. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
10. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
11. Novel method to make nanomaterials discovered
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2020)... ... March 04, 2020 , ... ... recombinant antibody products and services, today announced the launch of its FleXpress™ ... express a large number of antibodies at 80 ml scale. All production ...
(Date:2/28/2020)... ... February 26, 2020 , ... Designed primarily for ... with a dedicated controller, thus simplifying setup, streamlining integration, and optimizing workflow. Capable ... first of Fastec Imaging’s new HS Series cameras to be released. The HS ...
(Date:2/21/2020)... ... February 21, 2020 , ... Join Forrest Brown, Engineering Services ... Sequence, Inc. for an informative session on Wednesday, February 26, ... Key elements to incorporate into facility design to add manufacturing flexibility in the future, ...
(Date:2/13/2020)... ... February 12, 2020 , ... Arriello , a ... adopting Veeva Vault Safety™ as part of the company’s continued growth ... data, processing of safety information such as SUSARs and ICSRS, aggregate report production, ...
Breaking Biology Technology:
(Date:3/20/2020)... ... 20, 2020 , ... ImStem Biotechnology, Inc. (Farmington CT), a ... stem cells (hES-MSC), through a proprietary method using a trophoblast intermediate stage (hence ... diseases, today announced that the U.S. Food and Drug Administration (FDA) has lifted ...
(Date:3/19/2020)... FORT LAUDERDALE, Fla. (PRWEB) , ... March 19, 2020 , ... ... is bestowing his talents as host to the informational show "In Depth". The TV ... of people. "In Depth" is shifting gears on a new episode with a dive ...
(Date:3/13/2020)... ... March 13, 2020 , ... According to the American ... conjunctivitis and possibly be transmitted by aerosol or direct contact with the conjunctiva, ... take special precautions to avoid contracting the coronavirus. Touching the eyes while inserting ...
Breaking Biology News(10 mins):